SCHEMBL8668525

SCHEMBL8668525

OCCC(CCO)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.50
THRB P10828 1/20 0.33
CETP P11597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1426213 0.88 DPP4 (0.46) DPP4THRB
SCHEMBL28309756 0.85 DPP4 (0.43) DPP4
SCHEMBL1129965 0.83 DPP4 (0.42) DPP4
SCHEMBL8434197 0.83 FDPS (0.38) DPP4
SCHEMBL14615220 0.79 DPP4 (0.39) DPP4
SCHEMBL4323321 0.79 DPP4 (0.39) DPP4
SCHEMBL12270637 0.78 DPP4 (0.33) DPP4
SCHEMBL27823946 0.77 DPP4 (0.37) DPP4
SCHEMBL27823940 0.77 DPP4 (0.37) DPP4
SCHEMBL4330194 0.74 DPP4 (0.34) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055321-A1 PYRIMIDOPYRROLE SPIRO COMPOUNDS AND DERIVATIVES THEREOF AS DNA-PK INHIBITORS MEDSHINE DISCOVERY INC. (CN) 2023-02-23 US disclosed
EP-2852573-B1 N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma AG (DE) 2017-02-01 EP disclosed
EP-2852573-B1 N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma AG (DE) 2017-02-01 EP disclosed
US-9309198-B2 N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-12 US disclosed
US-9309198-B2 N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-12 US disclosed
US-9309198-B2 N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-12 US disclosed
US-20150152050-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-04 US disclosed
US-20150152050-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-04 US disclosed
US-20150152050-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-04 US disclosed
EP-2852573-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma Aktiengesellschaft (DE) 2015-04-01 EP disclosed
WO-2013174736-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2013-11-28 WO disclosed
US-5817602-A Herbicidal thiadiazabicyclodecanes NOVARTIS CORPORATION (US) 1998-10-06 US disclosed
EP-0705267-B1 HERBICIDAL THIADIAZABICYCLODECANES CIBA GEIGY AG (CH) 1997-08-13 EP disclosed
EP-0705267-A1 HERBICIDAL THIADIAZABICYCLODECANES CIBA GEIGY AG (CH) 1996-04-10 EP disclosed
WO-1995000521-A1 HERBICIDAL THIADIAZABICYCLODECANES CIBA-GEIGY AG (CH) 1995-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152050-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE GUCY1A2, GUCY1A1, GUCY1B2 DPP4 677/4885THRB 2098/4885CETP 1688/4885
US-20230055321-A1 PYRIMIDOPYRROLE SPIRO COMPOUNDS AND DERIVATIVES THEREOF AS DNA-PK INHIBITORS TYMP, DTYMK, PNKP DPP4 1192/4885THRB 2965/4885CETP 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.